{
  "report_rows": [
    {
      "kpi": "Adjusted diluted EPS",
      "prediction": "IN-LINE",
      "answer": "pred ~$1.77 vs. cons $1.765",
      "confidence": "LOW"
    },
    {
      "kpi": "Japan new premiums",
      "prediction": "IN-LINE",
      "answer": "pred ~\u00a520.80B vs. cons \u00a520.96B",
      "confidence": "LOW"
    },
    {
      "kpi": "U.S. new premiums",
      "prediction": "BEAT",
      "answer": "pred ~$359M vs. cons $354.8M",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Japan benefit ratio (FY26)",
      "prediction": "UNCHANGED",
      "answer": "guide ~60%-63% vs. cons 61.67%",
      "confidence": "LOW"
    },
    {
      "kpi": "U.S. benefit ratio (FY26)",
      "prediction": "LOWER",
      "answer": "guide ~48%-52% vs. cons 49.36%",
      "confidence": "LOW"
    },
    {
      "kpi": "Japan sales commentary (FY26)",
      "prediction": "UNCHANGED",
      "answer": "guide ~\u00a580B vs. cons \u00a579.00B",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -1.5,
  "day1_confidence": "LOW",
  "day5_residual_pct": -2.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 in-line EPS plus maintained ranges",
  "day5_confidence": "LOW"
}